Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA position on sampling

Executive Summary

Pharmaceutical Research & Manufacturers of America board agrees July 14 to policy language recommended by PhRMA's key issue team on sampling, essentially putting off any formal change in policy until next year in deference to continuing disagreement within the association and the KIT regarding a sampling ban. The adopted language states that "PhRMA should acknowledge that its existing position on sampling legislation [i.e., opposition to any ban] may not be up to date and should be thoroughly reviewed in consideration of recent legislative and regulatory proposals." The KIT "will continue, during the next few months, to analyze the issues and develop relevant legislative options," and the PhRMA board "will review the options developed by the KIT and adopt a new PhRMA policy at the February 1995 strategic planning meeting." PhRMA will continue its current opposition to a ban while it reviews policy options. "The Pink Sheet" incorrectly reported July 11 (p. 3) that the language calls for PhRMA to formally lift its opposition for this year

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS024792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel